Is the price fair?
What HAE's price assumes
Haemonetics Corporation trades at 52.0× earnings against 33.4× for the median Medical Devices name, more expensive than its own group.
52.0
Trailing P/E · Medical Devices median 33.4 · 1.56× the median: the market pays up for this one
- Price / sales
- 1.83
Price / sales · as of 2026-Q1
- Free cash flow yield
- 7.7%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- −0.14%
Growth the price implies · The price pays for −0.14% free cash flow growth a year for a decade; the business has delivered +47% a year over the last three.
Details›
- Price / book2026-Q1
- 3.07
- EV / EBIT2026-Q1
- 21.9
- EV / sales2026-Q1
- 2.58
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $260M
- Market capitalisation
- $3.37B
- 3-year revenue growth
- +4.5%
- 3-year free cash flow growth
- +47%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 21.3× today against a 54.1× median |
| 52-week range | $47.67 – $108.76 |
| Today | $106.58 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.